LEO Pharma’s Post

LEO Pharma delivered a profitability (EBITDA) uplift of DKK 2.1 billion in 2023, corresponding to a 20%-point margin improvement. We exceeded our profitability guidance and reached the upper range of our revenue growth guidance provided in March 2023. Our transformation is progressing according to plan guided by a clear strategy to make a significant impact in medical dermatology. Learn more about our results and ambitions in our Annual Report at https://lnkd.in/egBpRuK #LEOPharma #DermatologyBeyondTheSkin

#HiRO team ability to #start up #fast #Fasttimeline #Promiseoncommitment #Deliver #Indepthknowledge #Efficientprocess #Flexibilitytoadapt #Dynamic #Excellentprojectmanagement #Medicalaffairs #Medicalmonitor #Medicalwriting #Pharmacovigilance #Innovation #Pharmaceutical #Lifescience #Research #Healthcare #Artificialintelligence #Drugdevelopment #Clinicaloperationexcellence

AI in Dermatology - the best news of 2024 for Dermatology & now the future is bright! Empowering the Next Generation of Artificial Intelligence in Dermatology: the Journal of Investigative Dermatology Datasets and Benchmarks. https://lnkd.in/ezH3fcjz Thanks to Roxana Daneshjou and Harald Kittler #ai #dermatology #dermatologia

New Publication in Dermatology and Therapy: The analysis of an IL-13 inhibitor across EASI body regions and clinical signs of Atopic Dermatitis, results from ADvocate 1 & ADvocate 2 trials. View the full publication here: https://e.lilly/4ayAaKR

Latest Journal of Drugs in Dermatology (JDD) Podcast with the amazing Dr. Zoe Draelos talking about the broad importance of diversity, from microbiota to making sure your clinical studies, even for OTC, are inclusive, to ensure your data (and there is some nice data here) can be generalizable. https://lnkd.in/eRymg5Gi

I am privileged to share our new article published in the American Journal of Clinical Dermatology, which focuses on the use of topical calcineurin inhibitors on atopic dermatitis patients among the Taiwanese population. Please feel free to discuss and share your comments with me! https://lnkd.in/gYnFpfMh #atopicdermatitis #cohortstudy #topicalcalcineurininhibitors #NationalHealthinsuranceResearchDatabase

I’ll be in Berlin for the 5th Dermatology Drug Development Summit, Europe! Comment below if I'll see you there! Hear from Parexel at the event and visit us at booth #2. For more information on our speaking sessions, or to schedule a meeting with us, follow the link below. #Dermatology #DrugDevelopment #ClinicalResearch

How do you integrate new, largely clinically untested, therapeutic technology platforms with deep biological, clinical, regulatory, marketing, and distribution in highly specific diseases? Today, etherna announces ( https://lnkd.in/eHEzbEcn) one approach to this problem by partnering with Almirali, a leader in dermatology in order to usher in a new generation of mRNA drugs for skin diseases. This capitalizes on the synergy between state of the art custom LNP-mRNA capabilities (etherna) and world class knowledge and execution capabilities in an important organ system. Other partnerships are soon to follow. Many technology platform companies are caught between two worlds, having to optimize a clinically unproven technology platform, deliver this optimized platform to partners, and then to identify/execute/fund internal programs towards a specific drug target or disease, often without the depth of biological/clinical/regulatory/marketing know-how in this specific area. As a result, poor choices are made for the internal candidate and the outcome of the platform companies becomes an open question. Such has been the fate of many platform companies currently, and why they are falling out of favor at this moment. This has been the conundrum also for companies moving from mRNA vaccines (where the path is clear) to mRNA therapeutics where there are many options but where POC in the clinic is yet to be fully achieved. Now that I am formally retired from academia ( https://lnkd.in/eekppGWm), I am hoping to use my deep knowledge and biological intuition in the of CV/metabolic/renal diseases to work with partners, including etherna, to enhance the development of a new generation of mRNA drugs. Looking forward to future interactions with my many colleagues in the biotechnology arena going forward.

Our Chief Scientific Officer, Karl Ziegelbauer, was recently interviewed by AseBio - Asociación Española de Bioempresas to discuss Almirall's innovation and development strategy. During the interview, Dr. Ziegelbauer reviewed Almirall's roadmap focused on medical dermatology, the main challenges and the company's R&D priorities. Find out more details below! #Innovation #MedicalDermatology

[WEBINAR] 📅 On March 26th, Loïc COLOMB (Newtone Technologies), Dr. Sabrina Höfling (PhD) (Monasterium Laboratory Skin & Hair Research Solutions GmbH) & Frederic Dubor, PhD - QIMA Life Sciences (QIMA Life Sciences) presented a webinar on 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵.   💻 If you missed this #Webinar, or if you would simply like to watch it again, you can access the recording here: https://lnkd.in/daqytXa4   👩🔬 In this presentation, you will: - Learn more about the role of clinical research in the Cosmetic & Dermatology industries - Discover some of the limitations encountered during clinical studies - Discover how the analysis of clinical samples and digital imaging can help you maximize the chances of success of your studies - Explore 3 examples of these approaches working together to help you correlate clinical signs and mechanisms of action ...and learn how to strengthen your clinical studies in a differentiating and innovative way ✨ #Comestics #Dermatology #Research --- If you want to learn more about what we do, you can reach out to us at ls@qima.com or directly on our website: https://lnkd.in/e6mgSewu